LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Closed

SectorHealthcare

433.1 -0.04

Buy Sell

Overview

Share price change

24h

Current

Min

432.05

Max

438.16

Key metrics
By Trading Economics
Income	-160M 1B
Sales	-240M 3B
P/E Sector Avg	25.91 49.701
EPS	4.47
Profit margin	34.531
Employees	6,400
EBITDA	-215M 1.1B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+29.84% upside

Dividends
By Dow Jones
Next Earnings	3 Aug 2026

Market Stats
By TradingEconomics
Market Cap	2.4B 111B
Previous open	433.14
Previous close	433.1

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

428.545 / 498.65 Support & Resistance

Vertex Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 May 2026, 20:57 UTC

Earnings

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 Feb 2026, 21:47 UTC

Earnings

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 Nov 2025, 21:44 UTC

Earnings

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 Aug 2025, 00:05 UTC

Hot Stocks

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 Aug 2025, 21:21 UTC

Earnings

Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 May 2026, 20:02 UTC

Earnings

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 May 2026, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 May 2026, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 May 2026, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 May 2026, 20:01 UTC

Earnings

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 Feb 2026, 21:13 UTC

Earnings

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 Feb 2026, 21:13 UTC

Earnings

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 Feb 2026, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 Feb 2026, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 Feb 2026, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 Feb 2026, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 Nov 2025, 21:05 UTC

Earnings

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 Nov 2025, 21:02 UTC

Earnings

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 Nov 2025, 21:02 UTC

Earnings

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 Nov 2025, 21:02 UTC

Earnings

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 Nov 2025, 21:02 UTC

Earnings

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 Aug 2025, 20:44 UTC

Earnings

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 Aug 2025, 18:17 UTC

Earnings

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 Aug 2025, 15:25 UTC

Earnings

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 Aug 2025, 14:12 UTC

Earnings

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 Aug 2025, 11:27 UTC

Earnings

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 Aug 2025, 10:55 UTC

Earnings

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 Aug 2025, 10:36 UTC

Earnings

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 Aug 2025, 10:18 UTC

Earnings

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Peer Comparison

Price change

Vertex Pharmaceuticals Inc Forecast

Price Target

By TipRanks

29.84% upside

12 Months Forecast

Average 562.9 USD 29.84%

High 641 USD

Low 436 USD

Based on 24 Wall Street analysts offering 12 month price targets forVertex Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

24 ratings

Buy

Hold

Sell

Based on 24 analysts giving stock ratings to Vertex Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

428.545 / 498.65Support & Resistance

Recent bearish events outweigh bullish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.